Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G T Budd

Showing results (11-20 of 70) with videos related to

Pageof 7
Sort By:
Investigational New Drugs|January 1, 1984
5-Fluorouracil and folinic acid: a Phase I-II trial in gastrointestinal malignancyJ Cunningham, R M Bukowski, G T Budd, et al.
Stem Cells (Dayton, Ohio)|January 1, 1993
Interleukin-2: use in solid tumorsR M Bukowski, D McLain, T Olencki, et al.
Seminars in Oncology|May 29, 1999
Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostineG T Budd, R Ganapathi, L Wood, et al.
Cancer Research|January 15, 1994
Estrogen receptor mutations in tamoxifen-resistant breast cancerP S Karnik, S Kulkarni, X P Liu, et al.
Investigational New Drugs|January 1, 1986
Phase I trial of intraperitoneal chemotherapy with 5-fluorouracil and citrovorum factorG T Budd, M J Schreiber, E Steiger, et al.
Journal of Surgical Oncology|November 1, 1983
Treatment of advanced ovarian cancer with cisplatin, adriamycin, and cyclophosphamide: effect of treatment and incidence of intracranial metastasesG T Budd, K D Webster, R R Reimer, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1984
Phase-I trial of UltrapureTM human leukocyte interferon in human malignancyG T Budd, R M Bukowski, L Miketo, et al.
Investigational New Drugs|September 5, 2002
A phase I trial of weekly gemcitabine and subcutaneous interferon alpha in patients with refractory renal cell carcinomaF Perez-Zincer, T Olencki, G T Budd, et al.
Investigational New Drugs|February 1, 1993
Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancerG T Budd, R M Bukowski, A Lichtin, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2002
Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokineticsD Z Chang, T Olencki, G T Budd, et al.
Pageof 7

Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
Investigational New Drugs|January 1, 1984
5-Fluorouracil and folinic acid: a Phase I-II trial in gastrointestinal malignancyJ Cunningham, R M Bukowski, G T Budd, et al.
Stem Cells (Dayton, Ohio)|January 1, 1993
Interleukin-2: use in solid tumorsR M Bukowski, D McLain, T Olencki, et al.
Seminars in Oncology|May 29, 1999
Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostineG T Budd, R Ganapathi, L Wood, et al.
Cancer Research|January 15, 1994
Estrogen receptor mutations in tamoxifen-resistant breast cancerP S Karnik, S Kulkarni, X P Liu, et al.
Investigational New Drugs|January 1, 1986
Phase I trial of intraperitoneal chemotherapy with 5-fluorouracil and citrovorum factorG T Budd, M J Schreiber, E Steiger, et al.
Journal of Surgical Oncology|November 1, 1983
Treatment of advanced ovarian cancer with cisplatin, adriamycin, and cyclophosphamide: effect of treatment and incidence of intracranial metastasesG T Budd, K D Webster, R R Reimer, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1984
Phase-I trial of UltrapureTM human leukocyte interferon in human malignancyG T Budd, R M Bukowski, L Miketo, et al.
Investigational New Drugs|September 5, 2002
A phase I trial of weekly gemcitabine and subcutaneous interferon alpha in patients with refractory renal cell carcinomaF Perez-Zincer, T Olencki, G T Budd, et al.
Investigational New Drugs|February 1, 1993
Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancerG T Budd, R M Bukowski, A Lichtin, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2002
Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokineticsD Z Chang, T Olencki, G T Budd, et al.
Pageof 7